FDA Oncology Announcements

Alkylating agent × Thoracic × Clear all

3 Announcements

FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancer

Trial: IMforte
Drugs: Zepzelca (lurbinectedin) · Alkylating agent, Tecentriq (atezolizumab) · Anti-PD-L1 antibody, Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) · Anti-PD-L1 antibody
Condition: Thoracic

FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer

Drug: ZEPZELCA (lurbinectedin) · Alkylating agent
Condition: Thoracic

FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer

Drug: ZEPZELCA (lurbinectedin) · Alkylating agent
Condition: Thoracic